Nuclera
PrivateLast Round
Series C
Extension
Jan 13, 2026
Est. Valuation
$17.09M
Total Funding Raised
$211.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nuclera is a biotechnology company that develops automated protein prototyping systems to accelerate drug discovery workflows.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Drug Discovery, 3D Printing
Business Model
B2B
Customer Profile
Hardware Sales, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuclera Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Nuclera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jan 13, 2026 | ||||
| Series C | Oct 16, 2024 | ||||
| Grant | Jun 6, 2024 | ||||
| Grant | Dec 6, 2023 | ||||
| Series B Extension | Jul 6, 2022 | ||||
Series B | Feb 2, 2022 |
Key People
Founding team and executive leadership
Nuclera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Amadeus Capital Partners | Series B |
| Verve Ventures | Series B Extension, Series C, Series C Extension, Series B |
| G. K. Goh Holdings Pte. Ltd. | Series C Extension, Series B, Series C |
| Future Planet Capital Regional | Series B |
| RT Ventures | Series A |
| Patient Square Capital | Series C, Series C Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 30, 2026
Launched nanodisc panel for GPCR screening and scale-up.
- Mar 29, 2026
Received an award at the One Nucleus Awards 2026.
Nuclera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Nuclera's valuation, stock price, and market status.